The content on this site is intended for healthcare professionals only
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic r...
Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
19 Sep 2021
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of adv...
Dr Naveen Vasudev - Leeds Cancer Centre, Leeds, UK
19 Sep 2021
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advan...
Dr Jeroen Van Dorp - Netherlands Cancer Institute, Amsterdam, The Netherlands
18 Sep 2021
Cabozantinib in combination with atezolizumab in patients with mCRPC
Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, US...
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
18 Sep 2021
Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or local...
Prof Thomas Powles - Queen Mary University of London, London, UK
17 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
17 Sep 2021
OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
31 Aug 2021
OncoAlert and ecancer weekly round up for August 16th - August 22nd, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
23 Aug 2021
Current state of prostate cancer in Antigua and Barbuda
Dr Adrian Rhudd - Mount St. John’s Medical Centre, Antigua, Antigua and Barbuda
18 Aug 2021
OncoAlert and ecancer weekly round up for August 2 - August 14, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
16 Aug 2021
Patterns of recurrence after a radical nephroureterectomy in high-risk upper tra...
Dr Alberto Martini - Vita-Salute San Raffaele University, Milan, Italy
26 Jul 2021
